News Bluebird bio details plans to file three blockbusters Biotech looks to take on Novartis, Gilead, and Juno in CAR-T
News Celgene in talks to buy CAR-T partner Juno Celgene is understood to be in talks to buy CAR-T specialists Juno Therapeutics, in a deal which could be worth around $7 billion.
News Cellectis gets FDA go-ahead to restart fatal CAR-T trial Regulator agrees to restart phase 1 trial of UCART 123
News Kite in CAR-T pole position as rolling submission begins Kite to start filing data for KTE-C19 with US regulator.
Oncology Hernexeos and what’s next, with Vicky Brown At Reuters Pharma USA this week, Boehringer Ingelheim's Vicky Brown spoke with us about the company's recent approval for Hernexeos in NSCLC.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
